Combination of Adoptive Cell Transfer and Antibody Injection Can Eradicate Established Tumors in Mice-An in vivo study using anti-OX40mAb, anti-CD25mAb and anti-CTLA4mAb-

被引:7
|
作者
Watanabe, Akira [1 ]
Hara, Masaki [1 ]
Chosa, Eiichi [1 ]
Nakamura, Kunihide [1 ]
Sekiya, Ryo [1 ]
Shimizu, Tetsuya [1 ]
Onitsuka, Toshio [1 ]
机构
[1] Miyazaki Univ, Fac Med, Dept Cardiovasc Thorac & Gen Surg, Miyazaki, Japan
关键词
REGULATORY T-CELLS; ANTITUMOR IMMUNITY; TGF-BETA; CANCER; CTLA-4; IMMUNOTHERAPY; ANTIGEN; LYMPHOCYTES; VACCINATION; ACTIVATION;
D O I
10.3109/08923970903222355
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Boosting an effective immune response against established tumors remains a difficult challenge. This study shows the combination of 1) adoptive cell transfer using CD25 depleted splenocytes co-cultured with irradiated tumor cells, and 2) antibody injection therapy using CTLA4 blockade, the elimination of Treg and OX40, which together could eradicate an established MethA tumor in over 50% of the BALB/c mice. Each element of the protocol was shown to be necessary, as elimination of any factor except anti-CD25 antibody injection failed to eradicate the tumor.</.
引用
收藏
页码:238 / 245
页数:8
相关论文
共 3 条
  • [1] Preliminary safety and efficacy results from phase Ib study of the anti-CTLA-4 monoclonal antibody (mAb) CS1002 in combination with anti-PD-1 mAb CS1003 in patients with advanced solid tumors
    Bishnoi, S.
    Cosman, R.
    Moore, M.
    Eek, R.
    Mant, A.
    Zielinski, R.
    Chan, L. S.
    Ma, Y.
    Zhang, Q.
    Yau, T.
    Aghmesheh, M.
    Tse, A. N.
    ANNALS OF ONCOLOGY, 2021, 32 : S840 - S840
  • [2] Preliminary safety and efficacy results from phase Ib study of the anti-CTLA-4 monoclonal antibody (mAb) CS1002 in combination with anti-PD-1 mAb CS1003 in patients with advanced solid tumors
    Bishnoi, S.
    Yau, T.
    Cosman, R.
    Aghmesheh, M.
    Moore, M.
    Chan, S. L.
    Mant, A.
    Eek, R.
    Zielinski, R.
    Li, P.
    Wang, H.
    Ma, Y.
    Tse, A.
    ANNALS OF ONCOLOGY, 2021, 32 : S1437 - S1438
  • [3] Phase I study of combination immunotherapy with agonistic CD40 monoclonal antibody (mAb) CP-870,893 (aCD40) and anti-CTLA-4 antibody tremelimumab (treme) in patients with metastatic melanoma
    Bajor, David L.
    Mick, Rosemarie
    Riese, Matthew J.
    Lee, Richman P.
    Xu, Xiaowei
    Torigian, Drew A.
    Stelekati, Erietta
    Sweeney, Martha
    Sullivan, Brendan J.
    Schuchter, Lynn M.
    Amaravadi, Ravi
    Wherry, E. John
    Vonderheide, Robert H.
    CANCER IMMUNOLOGY RESEARCH, 2015, 3 (10)